VANCOUVER, BC and
MESA, AZ, July 10, 2013 /PRNewswire/ - Avidus Management
Group Inc. ("Avidus" or the "Company") (TSX-V: AVD, OTC: ASNHF) and
its wholly owned subsidiary, Asantae, Inc. today announced the
details of its new functional beverage, IS2.
IS2 is a specialized, proprietary formula that
uses high potency extracts and bioavailable nutrients including
Astralagus, Curcumin, and Resveratrol to support the body's natural
ability to protect, fight, and rebuild against the effects of
injury, illness, and disease.
The IS2 formula uses research done at many of
the top nutraceutical and nutritional institutes in North America to identify the specific dosages
and combinations needed to provide optimal benefits.
Dan Lundell, CEO
said, "We are very excited about the launch of this revolutionary
beverage this fall. We are confident that this product will provide
significant health benefits and create excitement within our
network that will accelerate recruiting and revenue growth.
Mr. Ridley's experience and prior success within the functional
beverage category make this product launch an exciting strategic
growth opportunity as well as a natural extension of our mission to
fight the root causes of disease."
Doug Ridley,
President, added, "Having built a company from the ground up, and
led a successful network of distributors that generated annual
sales of over $25 million, both
focused on a functional beverage product, I am thrilled about the
pending launch of IS2. The functional beverage space represents an
enormous opportunity and we expect IS2 to drive our intensive
recruitment and growth initiatives."
About Avidus
Avidus Management Group Inc. (www.asantae.com)
(TSX-V: AVD, OTC: ASNHF) through its wholly owned subsidiary,
Asantae, Inc. develops, produces and markets innovative nutritional
products through direct and network marketing channels. The
ingredients in Avidus' products have been shown to reduce chronic
low-grade inflammation and oxidative stress, and support a healthy
immune system that, according to scientific and medical research,
are the underlying conditions for most modern epidemic diseases
(diabetes, heart disease, obesity, stroke, etc.).
This news release may contain forward-looking statements
relating to the Company's operations or to the environment in which
it operates. Such statements are based on operations, estimates,
forecasts and projections. They are not guarantees of future
performance and involve risks and uncertainties that are difficult
to predict and may be beyond the Company's control. A number of
important factors could cause actual outcomes and results to differ
materially from those expressed in forward-looking statements,
including those set forth in the Company's regulatory filings. In
addition, such statements relate to the date on which they are made
and the Company disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, save and except as may be
required by applicable securities laws.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE Avidus Management Group Inc.